TRIDENT-1: A global, multicenter, open-label Phase II study investigating the activity of repotrectinib in advanced solid tumors harboring ROS1 or NTRK1-3 rearrangements.
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Robert Charles Doebele, Jessica Jiyeong Lin, Misako Nagasaka, Viola Weijia Zhu, Nashat Y. Gabrail, Lyudmila Bazhenova, Peter Meade Anderson, Benjamin J. Solomon, Arkadiusz Z. Dudek, Andrew William Pippas, Mihran Shirinian, Christina S Baik, Shanna Stopatschinskaja, D. Ross Camidge, Byoung Chul Cho, Alexander E. Drilon
Institutions: Massachusetts General Hospital, The Barbara Ann Karmanos Cancer Institute, University of California, Irvine, UC Irvine Chao Family Comprehensive Cancer Center, Gabrail Cancer Center, University of California San Diego, Cleveland Clinic, Peter MacCallum Cancer Centre, HealthPartners, Adventist Health Glendale, Fred Hutch Cancer Center, University of Colorado Anschutz, Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital, Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3029454977